<DOC>
	<DOCNO>NCT00992589</DOCNO>
	<brief_summary>The purpose study assess effectiveness safety rabeprazole sodium , inhibitor gastric acid secretion protein pump inhibitor ( PPI ) class , compare placebo treatment gastrointestinal esophageal reflux disease ( GERD ) infants 1 11 month age .</brief_summary>
	<brief_title>Safety Efficacy Rabeprazole Infants With Gastroesophageal Erosive Reflux Disease ( GERD )</brief_title>
	<detailed_description>Rabeprazole sodium belongs class drug know proton pump inhibitor , suppress gastric acid secretion . The drug approve United States treatment adult GERD acid-related gastrointestinal disorder , study adolescent ( old 12 year age ) result similar adult . However , drug study child age 12 year . This study focus efficacy safety rabeprazole sodium infant age 1 11 month , pediatric group prevalence GERD-related symptom great . This multicenter , double-blind , randomize , placebo-controlled , parallel-group withdrawal study compare efficacy safety 2 dos ( 0.5 mg/kg 1.0 mg/kg daily ) rabeprazole placebo treatment infant age 1 11 month diagnosis suspect GERD , symptomatic GERD , endoscopically histologically proven GERD . The study consist 3 study period : screening period 10 day , open-label treatment period 3 week , 5-week double-blind treatment period . Patients receive GERD therapy screen GERD therapy discontinue 3 day enter open-label treatment period . Patients positive clinical response accord Clinical Global Impressions - Improvement ( CGI-I ) scale end first second week open-label treatment period enter double-blind treatment period ; withdrawn study . A parent , legal guardian , individual experience care infant primary caregiver , responsible daily weekly assessment study drug administration . Efficacy assessment consist Infant Gastroesophageal Reflux Questionnaire Revised ( I GERQ-R ) total score , Infant Gastroesophageal Reflux Questionnaire-Daily Diary ( I GERQ-DD ) total score , CGI-I , Global Treatment Satisfaction Score , weight-for-age Z-score . Safety assessment include monitor concomitant therapy adverse event throughout study ; clinical laboratory testing ( hematology , clinical chemistry , urinalysis ) , measurement vital sign ( pulse respiratory rate , blood pressure , temperature ) ; physical examination include length weight . The study hypothesis rabeprazole sodium superior placebo treatment GERD infant age 1 11 month . Rabeprazole sodium capsule ( ) mouth day , 10.0 milligram ( mg ) /kilogram ( kg ) 3 week open-label treatment period either 5.0 mg/kg 10.0 mg/kg 5-week double-blind treatment period . To give study drug infant , content capsule ( ) sprinkle onto small amount soft food , need , content capsule ( ) may give small amount ( 5 milliliter [ mL ] ) infant formula express breast milk .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>Diagnosis suspect GERD , symptomatic GERD , endoscopically histologically proven GERD , base frequent vomit regurgitation , least 1 follow : ) poor weight gain , b ) irritability , excessive cry disturb sleep parent ( ) doctor consider abnormal ( due colic ) c ) refusal eat even hungry arch back meal weight 2.5 kg 15.0 kg IGERQR score &gt; 16 Have 1 caregiver addition parent ( ) History confirm acute lifethreatening event due GERD Known narrow open stomach small intestine Confirmed diagnosis cow 's milk allergy Have take PPIs H2blockers ( class drug inhibit stomach acid production ) several drug affect normal movement digestive tract ( caffeine , theophylline , antacid , erythromycin , others ) within 3 day enter study Have blood urine test result well normal range infant</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>11 Months</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Gastroesophageal Reflux</keyword>
	<keyword>Gastroesophageal Reflux Disease</keyword>
	<keyword>GERD</keyword>
	<keyword>Proton Pump Inhibitor</keyword>
	<keyword>PPI</keyword>
	<keyword>Regurgitation</keyword>
	<keyword>Infants</keyword>
	<keyword>AcipHex , PARIET</keyword>
	<keyword>ALFENCE</keyword>
</DOC>